Last updated: February 25, 2026
What is the drug associated with NDC 50458-0606?
NDC 50458-0606 refers to Siponimod (Mayzent), approved by the U.S. Food and Drug Administration (FDA) in March 2019. It is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS).
Market Overview
Market Size and Segments
The global multiple sclerosis (MS) treatment market was valued at approximately $19.7 billion in 2022. The segment for oral disease-modifying therapies (DMTs), which includes Siponimod, accounts for approximately $8.5 billion of this figure.
Market drivers:
- Increasing prevalence of MS worldwide, estimated at 2.8 million cases globally.
- Growing preference for oral DMTs over injectable therapies.
- Expanding approval for broader MS subtypes, including secondary progressive MS.
Key competitors:
| Drug Name |
Indication |
Market Share (2022) |
Price Range (per 30-day supply) |
| Siponimod (Mayzent) |
Relapsing MS, active SPMS |
15% |
$7,150 – $7,800 |
| Dimethyl Fumarate |
RRMS |
25% |
$6,900 – $7,600 |
| Ocrelizumab (Ocrevus) |
Primary progressive MS, RRMS |
20% |
$65,000 annually (~$5,417/month) |
| Alemtuzumab |
RRMS |
10% |
$88,000 per cycle |
Pricing Trends
Compared to other oral DMTs, Siponimod's price aligns with market norms for MS oral medications. Its cost range is approximately $7,150 to $7,800 monthly, reflecting competition with similar drugs like Fingolimod and Cladribine.
Revenue Projections
In 2022, Mayzent generated approximately $600 million globally. Projections for 2023 and 2024 estimate annual revenues of $700-800 million, assuming steady market share growth and expanded labeling.
Price Projection Factors
Regulatory and Reimbursement Landscape
- Insurance Coverage: Covers approximately 85% of U.S. patient prescriptions.
- Pricing pressures: Due to policy shifts toward value-based pricing and biosimilar competition for some MS agents.
- Potential for price reductions: Expected with increased biosimilar entries or negotiations at the federal and state levels.
Market Adoption and Competition
- Adoption rate among neurologists remains high due to efficacy and oral administration.
- Increasing use in secondary progressive MS broadens the patient base.
- Competition with drugs like Ocrevus and Cladribine, which are administered less frequently or have different efficacy profiles, influences pricing strategies.
Patent and Exclusivity Timeline
- U.S. patent protection for Siponimod extends until 2034.
- Patent challenges may influence pricing, but current patent protection sustains stable pricing for at least the next decade.
Patent Expiry and Biosimilar Entry
- Biosimilar market entry targeted post-2030, with no immediate impact expected.
- Small molecule generic competition unlikely before patent expiration.
Future Price Trends Prediction
| Year |
Estimated Price Range (monthly) |
Notes |
| 2023 |
$7,150 – $7,800 |
Current pricing level |
| 2024 |
$7,100 – $7,700 |
Slight downward pressure |
| 2025 |
$6,900 – $7,600 |
Increased competition potential |
| 2026 |
$6,800 – $7,400 |
Possible generic influence |
Note: Price decreases are constrained by patent protection, but reimbursement strategies and market competition may cause gradual reductions.
Key Takeaways
- NDC 50458-0606 (Siponimod) is a key player in the oral MS therapy segment, with steady revenue growth expected through 2025.
- Pricing remains relatively stable but faces downward pressure from reimbursement policies and potential biosimilar competition.
- Market expansion into secondary progressive MS broadens the patient base, supporting continued sales.
- Patent protections until 2034 provide pricing stability; biosimilar impact remains limited until patents expire.
- Price projections indicate marginal declines in the medium term, maintaining a cost range around $7,150 - $7,800 monthly.
FAQs
Q1: What are the factors influencing the price of Siponimod?
Patient access, market competition, patent status, payer negotiations, and policy shifts impact the price.
Q2: How does Siponimod compare to other MS treatments?
It offers an oral administration route, with a moderately high price point relative to oral therapies but lower than infusible options like Ocrevus.
Q3: When might biosimilars or generics impact its pricing?
Generics are expected post-2034, with biosimilars unlikely due to the small molecule nature of Siponimod.
Q4: Is the current market forecast optimistic for Siponimod?
Yes, due to its expanding indication scope and high physician adoption, though pricing pressures may limit profit margins over time.
Q5: What is the potential impact of new approvals or label expansions?
Additional indications could increase patient pools and sales, potentially stabilizing or increasing prices.
Sources
- MarketData, Grand View Research. (2023). MS treatment market analysis.
- FDA. (2019). Mayzent (Siponimod) approval documents.
- IQVIA. (2022). U.S. Prescription Drug Market Reports.
- Forbes. (2022). MS drug market and pricing dynamics.
- Evaluate Pharma. (2023). MS therapeutic landscape forecast.
